Choose A Condition: PLEASE SELECT MODERATELY TO SEVERELY ACTIVE RA ACTIVE PSORIATIC ARTHRITIS ACTIVE ANKYLOSING SPONDYLITIS Home Efficacy ACR Response in RA Inhibition of Radiographic Progression in RA HAQ-DI Scores in RA SF-36 Scores in RA Safety Safety Profile in RA: Placebo-Controlled Phase Safety Profile in RA: Controlled and Uncontrolled Phase Home Efficacy ACR Response in PsA Inhibition of Radiographic Progression in PsA Enthesitis/Dactylitis in PsA HAQ-DI in PsA SF-36 Scores in PsA PASI Response in PsA Safety Safety Profile in PsA: Placebo-Controlled Phase Home Efficacy ASAS Response BASDAI Scores BASFI/BASMI Scores ASQoL Scores ASAS Partial Remission Data Safety Safety Profile in AS: Placebo-Controlled Phase Home Efficacy Safety About SIMPONI ARIA® About SIMPONI ARIA® Dosing and Administration Dosing Dosing Calculator Interactive Infusion Video Administration Instructions Access and Affordability First-line Access Local Coverage Contract Purchase Program Resources And Support Janssen CarePath Additional Resources Important Safety Information Medical Information Center Request Information Patient Website
FOR ADULTS WITH ACTIVE PsA SIMPONI ARIA® is ready to fight the symptoms of active PsA. ABOUT SIMPONI ARIA® Learn about the only fully human anti-TNF IV therapy DEMONSTRATED EFFICACY Explore PsA treatment results with SIMPONI ARIA® with or without MTX from a clinical trial EFFICIENT INFUSION Provide patients with a 30-minute infusion once every 8 weeks after 2 starter doses at Weeks 0 and 41,2 "Efficient" is defined as the total amount of time required to administer SIMPONI ARIA® LEARN MORE Provide patients with a 30-minute infusion once every 8 weeks after 2 starter doses at Weeks 0 and 41,2 "Efficient" is defined as the total amount of time required to administer SIMPONI ARIA® LEARN MORE
DEMONSTRATED EFFICACY Explore PsA treatment results with SIMPONI ARIA® with or without MTX from a clinical trial
REQUEST INFORMATION
